We believe that the key gaps in research on portal hypertension include the lack of multicenter clinical trials involving combination therapies, where different compounds target distinct molecular pathways and exhibit varied mechanisms of action, such as the integration of NOX inhibitors and FXR agonists with conventional therapies like beta-blockers. The gene discussed is NR1H4; the disease is liver disorder.